[PDF][PDF] Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma
H Schmidt, JS Johansen, P Sjoegren… - Journal of Clinical …, 2006 - researchgate.net
H Schmidt, JS Johansen, P Sjoegren, IJ Christensen, BS Sorensen, K Fode, J Larsen…
Journal of Clinical Oncology, 2006•researchgate.netPurpose To evaluate the novel tumor biomarker YKL-40 in serial serum samples from
patients with American Joint Committee on Cancer (AJCC) stage I and II melanoma from the
time of diagnosis and during routine follow-up. Macrophages, neutrophils, and cancer cells
secrete YKL-40, and a high serum level has been associated with poor prognosis in patients
with several cancer types.
patients with American Joint Committee on Cancer (AJCC) stage I and II melanoma from the
time of diagnosis and during routine follow-up. Macrophages, neutrophils, and cancer cells
secrete YKL-40, and a high serum level has been associated with poor prognosis in patients
with several cancer types.
Purpose
To evaluate the novel tumor biomarker YKL-40 in serial serum samples from patients with American Joint Committee on Cancer (AJCC) stage I and II melanoma from the time of diagnosis and during routine follow-up. Macrophages, neutrophils, and cancer cells secrete YKL-40, and a high serum level has been associated with poor prognosis in patients with several cancer types.
researchgate.net
